Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy …
Aims Compared with placebo, abciximab has been associated with mortality reduction at
late follow-up. The TARGET trial was performed to test whether tirofiban and abciximab …
late follow-up. The TARGET trial was performed to test whether tirofiban and abciximab …
Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy …
D Mukherjee, E Topol, M Bertrand… - EUROPEAN HEART …, 2005 - air.unipr.it
Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous
coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year …
coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year …
[PDF][PDF] Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar …
D Mukherjee, EJ Topol, ME Bertrand… - European Heart …, 2005 - academia.edu
Aims Compared with placebo, abciximab has been associated with mortality reduction at
late followup. The TARGET trial was performed to test whether tirofiban and abciximab …
late followup. The TARGET trial was performed to test whether tirofiban and abciximab …
Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy …
D Mukherjee, EJ Topol, ME Bertrand… - European Heart …, 2005 - elibrary.ru
Aims Compared with placebo, abciximab has been associated with mortality reduction at
late follow-up. The TARGET trial was performed to test whether tirofiban and abciximab …
late follow-up. The TARGET trial was performed to test whether tirofiban and abciximab …
Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy …
D Mukherjee, EJ Topol, ME Bertrand… - European Heart …, 2005 - search.ebscohost.com
Aims Compared with placebo, abciximab has been associated with mortality reduction at
late follow-up. The TARGET trial was performed to test whether tirofiban and abciximab …
late follow-up. The TARGET trial was performed to test whether tirofiban and abciximab …
[PDF][PDF] Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar …
D Mukherjee, EJ Topol, ME Bertrand… - European Heart …, 2005 - researchgate.net
Aims Compared with placebo, abciximab has been associated with mortality reduction at
late followup. The TARGET trial was performed to test whether tirofiban and abciximab …
late followup. The TARGET trial was performed to test whether tirofiban and abciximab …
Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy …
D Mukherjee, EJ Topol, ME Bertrand, SD Kristensen… - 2005 - pubmed.ncbi.nlm.nih.gov
Aims Compared with placebo, abciximab has been associated with mortality reduction at
late follow-up. The TARGET trial was performed to test whether tirofiban and abciximab …
late follow-up. The TARGET trial was performed to test whether tirofiban and abciximab …
[引用][C] Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar …
D MUKHERJEE, EJ TOPOL… - European heart …, 2005 - pascal-francis.inist.fr
Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous
coronary revascularization : do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year …
coronary revascularization : do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year …
[PDF][PDF] Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar …
D Mukherjee, EJ Topol, ME Bertrand… - European Heart …, 2005 - Citeseer
Aims Compared with placebo, abciximab has been associated with mortality reduction at
late followup. The TARGET trial was performed to test whether tirofiban and abciximab …
late followup. The TARGET trial was performed to test whether tirofiban and abciximab …
Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy …
D Mukherjee, EJ Topol, ME Bertrand… - European Heart …, 2005 - europepmc.org
Aims Compared with placebo, abciximab has been associated with mortality reduction at
late follow-up. The TARGET trial was performed to test whether tirofiban and abciximab …
late follow-up. The TARGET trial was performed to test whether tirofiban and abciximab …